← All products

Reusable metal platform

Metal Reusable Injection Pen V2 — 60U

A reusable 3 mL metal pen with documented 0.01 mL increments and 0.60 mL maximum.

Primary container
Standard 3 mL cartridge
Dose increment
0.01 mL
Dose units
60
Dose / delivery range
0–0.60 mL
Drug names describe source-listed or potential evaluation scenarios. Final compatibility, intended use and authorization require program-specific evidence.

Product overview

A reusable 3 mL metal pen with documented 0.01 mL increments and 0.60 mL maximum. This platform is presented for technical screening; final suitability depends on the selected device configuration, formulation, primary container, use conditions and project-specific verification.

Source and evidence boundary

Published values are configuration-specific and remain subject to controlled internal evidence review. Supplier identities and source records are not public product claims.

Key product features

  • Standard 3 mL cartridge
  • 0.01 mL documented increment
  • 0–0.60 mL documented range

Technical specifications

The selected variant controls every value in this table. Values from other configurations are not merged.

Primary containerStandard 3 mL cartridge
Dose increment0.01 mL
Dose units60
Dose / delivery range0–0.60 mL
Application contextProgram-specific assessment
Device useReusable
CustomizationColor, logo, scale and packaging subject to review
Dimensions16 cm x 1.86 cm
MaterialsAluminium body
Needle interfaceISO 11608-2 pen needle interface
Closure systemStandard 3 mL cartridge per ISO 11608-3; glass barrel, plunger and lined aluminium seal cap
PackagingCustomisable: bag or tray, artwork reviewed as a project item
Minimum order quantity500 units per configuration
Production lead time2 weeks

Drug or application assessment

A reusable 3 mL metal pen with documented 0.01 mL increments and 0.60 mL maximum. Listed applications are screening contexts only. Compatibility and regulatory conclusions require project-specific evidence.

Cartridge & needle compatibility

Standard 3 mL cartridge is the documented primary-container format. Final dimensions, stopper system, needle interface and component compatibility must be confirmed for the selected configuration.

OEM / ODM configuration

Dose systemVariant-specific range and increment
AppearanceColor, logo and dose-scale artwork
Primary packCartridge or PFS assessment
Secondary packLabeling and packaging pathway

Validation & documentation

Project scope may include configuration drawings, risk inputs, dose-delivery verification, container and needle assessment, transport or aging considerations, and human-factors planning. Availability depends on the selected platform and agreed program.

Questions for platform selection

What is the formulation?Viscosity, concentration and stability affect delivery-system assessment.
What is the primary container?Cartridge or PFS geometry, stopper and closure details must be confirmed.
What is the target dose?Minimum, maximum, increment and dosing sequence belong to one verified variant.
Who will use it?User population, training, dexterity and feedback needs shape human-factors work.
Which market?Documentation and regulatory pathways vary by intended region.
What is customized?Functional, labeling and appearance changes have different validation impacts.

Why evaluate this platform with Penacta

Penacta separates platform screening from final compatibility claims. Device architecture, formulation, primary container, dose profile, user needs and market pathway are reviewed as one combination-product problem.

FAQ

What is documented for the 60-unit configuration?

The documented configuration uses Standard 3 mL cartridge, 0.01 mL dose increments, 60 dose units and a 0–0.60 mL delivery range. These values must remain together as one configuration.

What information is needed before requesting a quotation?

Share the formulation category, primary container, target dose and increment, intended users, target market, annual volume and the parts you want customized.

Does a drug name mean this pen is approved for that medicine?

No. A drug name identifies a sourcing or technical-evaluation scenario. Final compatibility, usability, labeling and regulatory conclusions require evidence for the actual drug–device combination.

Can parameters from different variants be combined?

No. The primary container, dose increment, units and delivery range remain tied to the selected documented configuration.

Can the color, logo and packaging be customized?

Appearance and packaging can be evaluated within the selected platform and project scope. Functional, scale and labeling changes require a separate technical review.